Argen X SE ADR Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
35.6%projected annual EPS growth
Analyst Coverage
22analysts covering
FY Revenue (est.)
$6.2Bnext fiscal year
FY EPS (est.)
$28.95next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Third Quarter 2026 Financial Results and Business Update | 22 Oct 2026 |
| Full-Year 2026 Financial Results and Fourth Quarter 2026 Business Update | 25 Feb 2027 |
Monitoring Framework
Key Performance Indicators
VYVGART Global Product Net Sales Quarterly1.5BTarget: Sustained double-digit sequential and year-over-year growth
Cash, Cash Equivalents and Current Financial Assets Quarterly5.2BTarget: Maintain strong liquidity to fund pipeline and acquisitions
Operating Profit Margin Quarterly32.0%Target: Maintain or exceed 30% operating margin through operational leverage
Watch Items
- Phase 3 ALKIVIA study readout in autoimmune myositisTrigger: Topline data release expected in Q3 2026Action: Evaluate clinical efficacy and safety profile to assess expansion of VYVGART into rheumatology.
- Phase 3 EMPASSION study readout for empasiprubart in multifocal motor neuropathy (MMN)Trigger: Topline data release expected in Q4 2026Action: Analyze data to validate argenx's second potential blockbuster franchise.
- Integration of Forte Biosciences and development of FB102Trigger: Acquisition close expected in Q3 2026Action: Monitor clinical progress of the first-in-class anti-CD122 antibody in vitiligo and celiac disease.
Research as of 2 Sep 2026